ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA

J. U. Gutterman, C. McBride, E. J. Freireich, G. Mavligit, E. Frei, Evan M Hersh

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Adjuvant immunotherapy with B.C.G. was administered by scarification to twenty-eight patients after surgical resection of recurrent advanced malignant melanoma (stage III and IV). A lyophilised strain of B.C.G. (Tice) was compared to liquid B.C.G. (Pasteur) in various doses. Eight out of nine patients treated with Tice B.C.G. are alive and disease-free beyond one year (median, 60+ weeks). Sixteen out of nineteen patients treated with Pasteur B.C.G. are still alive (median, 40+ weeks), but only eight of these are disease-free. There has been a significant decrease in the relapse-rate and a significant improvement in the survival of patients treated with Tice B.C.G. compared to similar patient treated by surgery alone. There has been only slight improvement in prognosis in Pasteur B.C.G. treated patients. High doses of Tice B.C.G. induced a striking improvement in delayed-hypersensitivity skin reactions. Immunotherapy with lyophilised Tice B.C.G. seems to improve the prognosis of patients with resectable advanced malignant melanoma.

Original languageEnglish (US)
Pages (from-to)1208-1212
Number of pages5
JournalThe Lancet
Volume301
Issue number7814
DOIs
StatePublished - Jun 2 1973
Externally publishedYes

Fingerprint

Active Immunotherapy
Mycobacterium bovis
Melanoma
Immunotherapy
Delayed Hypersensitivity
Recurrence
Skin
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gutterman, J. U., McBride, C., Freireich, E. J., Mavligit, G., Frei, E., & Hersh, E. M. (1973). ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA. The Lancet, 301(7814), 1208-1212. https://doi.org/10.1016/S0140-6736(73)90526-6

ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA. / Gutterman, J. U.; McBride, C.; Freireich, E. J.; Mavligit, G.; Frei, E.; Hersh, Evan M.

In: The Lancet, Vol. 301, No. 7814, 02.06.1973, p. 1208-1212.

Research output: Contribution to journalArticle

Gutterman, JU, McBride, C, Freireich, EJ, Mavligit, G, Frei, E & Hersh, EM 1973, 'ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA', The Lancet, vol. 301, no. 7814, pp. 1208-1212. https://doi.org/10.1016/S0140-6736(73)90526-6
Gutterman JU, McBride C, Freireich EJ, Mavligit G, Frei E, Hersh EM. ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA. The Lancet. 1973 Jun 2;301(7814):1208-1212. https://doi.org/10.1016/S0140-6736(73)90526-6
Gutterman, J. U. ; McBride, C. ; Freireich, E. J. ; Mavligit, G. ; Frei, E. ; Hersh, Evan M. / ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA. In: The Lancet. 1973 ; Vol. 301, No. 7814. pp. 1208-1212.
@article{19010c12a499404f8d1b26ae6326ae07,
title = "ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA",
abstract = "Adjuvant immunotherapy with B.C.G. was administered by scarification to twenty-eight patients after surgical resection of recurrent advanced malignant melanoma (stage III and IV). A lyophilised strain of B.C.G. (Tice) was compared to liquid B.C.G. (Pasteur) in various doses. Eight out of nine patients treated with Tice B.C.G. are alive and disease-free beyond one year (median, 60+ weeks). Sixteen out of nineteen patients treated with Pasteur B.C.G. are still alive (median, 40+ weeks), but only eight of these are disease-free. There has been a significant decrease in the relapse-rate and a significant improvement in the survival of patients treated with Tice B.C.G. compared to similar patient treated by surgery alone. There has been only slight improvement in prognosis in Pasteur B.C.G. treated patients. High doses of Tice B.C.G. induced a striking improvement in delayed-hypersensitivity skin reactions. Immunotherapy with lyophilised Tice B.C.G. seems to improve the prognosis of patients with resectable advanced malignant melanoma.",
author = "Gutterman, {J. U.} and C. McBride and Freireich, {E. J.} and G. Mavligit and E. Frei and Hersh, {Evan M}",
year = "1973",
month = "6",
day = "2",
doi = "10.1016/S0140-6736(73)90526-6",
language = "English (US)",
volume = "301",
pages = "1208--1212",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7814",

}

TY - JOUR

T1 - ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMA

AU - Gutterman, J. U.

AU - McBride, C.

AU - Freireich, E. J.

AU - Mavligit, G.

AU - Frei, E.

AU - Hersh, Evan M

PY - 1973/6/2

Y1 - 1973/6/2

N2 - Adjuvant immunotherapy with B.C.G. was administered by scarification to twenty-eight patients after surgical resection of recurrent advanced malignant melanoma (stage III and IV). A lyophilised strain of B.C.G. (Tice) was compared to liquid B.C.G. (Pasteur) in various doses. Eight out of nine patients treated with Tice B.C.G. are alive and disease-free beyond one year (median, 60+ weeks). Sixteen out of nineteen patients treated with Pasteur B.C.G. are still alive (median, 40+ weeks), but only eight of these are disease-free. There has been a significant decrease in the relapse-rate and a significant improvement in the survival of patients treated with Tice B.C.G. compared to similar patient treated by surgery alone. There has been only slight improvement in prognosis in Pasteur B.C.G. treated patients. High doses of Tice B.C.G. induced a striking improvement in delayed-hypersensitivity skin reactions. Immunotherapy with lyophilised Tice B.C.G. seems to improve the prognosis of patients with resectable advanced malignant melanoma.

AB - Adjuvant immunotherapy with B.C.G. was administered by scarification to twenty-eight patients after surgical resection of recurrent advanced malignant melanoma (stage III and IV). A lyophilised strain of B.C.G. (Tice) was compared to liquid B.C.G. (Pasteur) in various doses. Eight out of nine patients treated with Tice B.C.G. are alive and disease-free beyond one year (median, 60+ weeks). Sixteen out of nineteen patients treated with Pasteur B.C.G. are still alive (median, 40+ weeks), but only eight of these are disease-free. There has been a significant decrease in the relapse-rate and a significant improvement in the survival of patients treated with Tice B.C.G. compared to similar patient treated by surgery alone. There has been only slight improvement in prognosis in Pasteur B.C.G. treated patients. High doses of Tice B.C.G. induced a striking improvement in delayed-hypersensitivity skin reactions. Immunotherapy with lyophilised Tice B.C.G. seems to improve the prognosis of patients with resectable advanced malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0015912321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015912321&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(73)90526-6

DO - 10.1016/S0140-6736(73)90526-6

M3 - Article

C2 - 4122562

AN - SCOPUS:0015912321

VL - 301

SP - 1208

EP - 1212

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7814

ER -